Study of efficacy of two different drugs(magnesium sulphate versus dexmedetomidine) along with levobupivacaine(0.25 percent) in Bilateral transverse abdominis block in patients scheduled for lower segment cesarean section under subarachnoid block

comparison of efficacy for levobupivacaine (0.25 percent) with magnesium sulphate versus dexmedetomidine as adjuvant in ultrasound guided bilateral transverse abdominis plane block in patients scheduled for lower segment cesarean section under subarachnoid block - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082590

Enrollment

Registered

2025-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium

Interventions

Intervention1: Transverse abdominis block: levobupivacaine (0.25 percent) with magnesium sulphate as adjuvant Intervention2: Transverse abdominis block: Levobupivacaine (0.25 percent) with dexmedetomi

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age 18 years to 40 years 2 Elective and Emergency Caesarean section under subarachnoid block 3 ASA 2 and 3

Exclusion criteria

Exclusion criteria: 1 Age less than18 years and more than 40 years 2 Patient refusal 3 Allergic to Local anaesthetic 4 Bleeding disorders 5 Parturients who are already on MgSO4 for Pre eclampsia / Eclampsia

Design outcomes

Primary

Measure	Time frame
Compare the total duration of analgesia the intensity of post operative painTimepoint: 24 hours	—

Secondary

Measure	Time frame
Assess the total requirement of rescue analgesiaTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactProf Dr B Balamurugan

Chettinad hospital and research institute

drbala.srmc@gmail.com9841544566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026